Back to top
more

Arcturus Therapeutics Holdings (ARCT)

(Delayed Data from NSDQ)

$8.50 USD

8.50
635,882

-0.01 (-0.12%)

Updated Apr 8, 2026 04:00 PM ET

After-Market: $8.49 -0.01 (-0.12%) 5:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (143 out of 243)

Industry: Medical - Biomedical and Genetics

Brokerage Reports

Research for ARCT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Arcturus Therapeutics Holdings Inc. [ARCT]

Reports for Purchase

Showing records 1 - 20 ( 163 total )

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/27/2026

Daily Note

Pages: 14

Morning Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

03/26/2026

Company Report

Pages: 7

ROTH Conference: ARCT-810 (OTC) Type C Disclosure Mid-Year, LCI May Support ARCT-032 (CF)

Provider: Roth Capital Partners, Inc.

Analyst: WALSH A

Price: 25.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

03/04/2026

Company Report

Pages: 6

CF Study Design Tightened; Runway Into 2Q28

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

03/04/2026

Company Report

Pages: 10

ARCT: Reports 4Q25; CF 12-Week Study Confirmed at 10mg; OTC on Track; Reiterate Buy/$20 PT

Provider: Roth Capital Partners, Inc.

Analyst: WALSH A

Price: 25.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

03/04/2026

Daily Note

Pages: 10

Morning Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

01/23/2026

Daily Note

Pages: 12

Morning Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

01/22/2026

Company Report

Pages: 24

Multiple Free Call Options Ahead of 1H26 Catalysts; Initiate with BUY and $20 PT

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

11/11/2025

Company Report

Pages: 6

ARCT-032 on Track for 12 Week Study 1H26, Key Risks Unchanged

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

11/11/2025

Company Report

Pages: 6

ARCT-032 on Track for 12 Week Study 1H26, Key Risks Unchanged

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

10/24/2025

Company Report

Pages: 7

Downgrading to Neutral on CF Data Miss; Lowering PT to $12

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

09/04/2025

Daily Note

Pages: 16

Assuming Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 50.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

04/10/2025

Daily Note

Pages: 3

FDA Grants Fast Track Designation to ARCT-2304 for Influenza A H5N1; Interim Phase 1 Data Expected in 2H25; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

03/27/2025

Daily Note

Pages: 29

Avian Alert: Investing Ahead of the Next Public Health Emergency

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 75.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

03/07/2025

Company Report

Pages: 8

4Q Recap: 2Q Data to Inform -032''s Potential in Valuable CF Market

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

02/14/2025

Daily Note

Pages: 4

Kostaive Approved By the European Commission as We Anticipated

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

01/31/2025

Daily Note

Pages: 5

Domestically Produced Kostaive Now Distributed in Japan; We Expect Kostaive''s EC Approval in February; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

01/13/2025

Daily Note

Pages: 4

LUNAR-H5N1 Could Be a Differentiated Vaccine for Potential H5N1 Pandemic; BARDA Fully Funds Phase 1 Study; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

01/07/2025

Industry Report

Pages: 4

Phase 2 Dosing Underway in CF and OTC Deficiency Patients; Interim Data From Both Expected in 1H25; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

12/17/2024

Daily Note

Pages: 4

CHMP Recommends Kostaive''s Approval As a COVID-19 Vaccine in Europe; We Look For U.S. BLA Filing in 1H25; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

11/08/2024

Company Report

Pages: 9

3Q Recap: Kostaive Sales Now Underway in Japan; Phase 2 CF Trial of ARCT-032 Now Screening Patients; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party